| P50 | author | Yuan-Tsong Chen | Q8933624 |
| P2093 | author name string | Priya S Kishnani | |
| | Sarah P Young | |
| | Andrea Amalfitano | |
| | David S Millington | |
| | Yan An | |
| | Deyanira Corz | |
| P2860 | cites work | Long-term safety and efficacy of enzyme replacement therapy for Fabry disease | Q24533551 |
| | Clinical and metabolic correction of pompe disease by enzyme therapy in acid maltase-deficient quail | Q24564823 |
| | Infusion of alpha-galactosidase A reduces tissue globotriaosylceramide storage in patients with Fabry disease | Q33179389 |
| | High-level production of recombinant human lysosomal acid alpha-glucosidase in Chinese hamster ovary cells which targets to heart muscle and corrects glycogen accumulation in fibroblasts from patients with Pompe disease | Q33598299 |
| | Recombinant human acid alpha-glucosidase enzyme therapy for infantile glycogen storage disease type II: results of a phase I/II clinical trial | Q33941289 |
| | Systemic correction of the muscle disorder glycogen storage disease type II after hepatic targeting of a modified adenovirus vector encoding human acid-alpha-glucosidase | Q35586463 |
| | Therapeutic response to intravenous infusions of glucocerebrosidase in a patient with Gaucher disease | Q37712754 |
| | Enzyme replacement therapy in late-onset Pompe's disease: a three-year follow-up | Q39218884 |
| | Efficacy of an adeno-associated virus 8-pseudotyped vector in glycogen storage disease type II. | Q40483404 |
| | Long-term intravenous treatment of Pompe disease with recombinant human alpha-glucosidase from milk | Q40534571 |
| | Isolation and characterisation of a recombinant, precursor form of lysosomal acid alpha-glucosidase | Q41258978 |
| | Multiple muscles in the AMD quail can be “cross‐corrected” of pathologic glycogen accumulation after intravenous injection of an [E1‐, polymerase‐] adenovirus vector encoding human acid‐α‐glucosidase | Q43966323 |
| | Analysis of a glucose tetrasaccharide elevated in Pompe disease by stable isotope dilution–electrospray ionization tandem mass spectrometry | Q44414194 |
| | Enzyme replacement therapy in mucopolysaccharidosis VI (Maroteaux-Lamy syndrome). | Q44883627 |
| | Improved efficacy of gene therapy approaches for Pompe disease using a new, immune-deficient GSD-II mouse model | Q45877711 |
| | Efficacy of gene therapy for a prototypical lysosomal storage disease (GSD-II) is critically dependent on vector dose, transgene promoter, and the tissues targeted for vector transduction | Q45884966 |
| | Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (laronidase). | Q47649434 |
| | Enzyme-replacement therapy in mucopolysaccharidosis I. | Q48705361 |
| | Recombinant human alpha-glucosidase from rabbit milk in Pompe patients. | Q55034196 |
| | Urinary excretion of a glucose-containing tetrasaccharide. A parameter for increased degradation of glycogen | Q67928042 |
| | Increased urinary excretion of a glycogen-derived tetrasaccharide in heterozygotes with glycogen storage diseases type II and III | Q72549527 |
| | Human acid alpha-glucosidase from rabbit milk has therapeutic effect in mice with glycogen storage disease type II | Q73142656 |
| | Liquid chromatographic assay for a glucose tetrasaccharide, a putative biomarker for the diagnosis of Pompe disease | Q73190685 |
| | Morphological changes in muscle tissue of patients with infantile Pompe's disease receiving enzyme replacement therapy | Q73437316 |
| | Analysis of sialyllactoses in blood and urine by high-performance liquid chromatography | Q74644746 |
| | Monitoring dose response of enzyme replacement therapy in feline mucopolysaccharidosis type VI by tandem mass spectrometry | Q75230690 |
| | Recombinant human acid alpha-glucosidase: high level production in mouse milk, biochemical characteristics, correction of enzyme deficiency in GSDII KO mice | Q77296912 |
| | Synthesis of novel internal standards for the quantitative determination of plasma ceramide trihexoside in Fabry disease by tandem mass spectrometry | Q77908026 |
| P433 | issue | 4 | |
| P921 | main subject | biomarker | Q864574 |
| | enzyme replacement therapy | Q916766 |
| | glucose monitoring | Q95987978 |
| P304 | page(s) | 247-254 | |
| P577 | publication date | 2005-08-01 | |
| P1433 | published in | Molecular Genetics and Metabolism | Q6895949 |
| P1476 | title | Glucose tetrasaccharide as a biomarker for monitoring the therapeutic response to enzyme replacement therapy for Pompe disease | |
| P478 | volume | 85 | |